← Back to home

AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY ENTERITIS

Clinical trials for AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY ENTERITIS explained in plain language.

Never miss a new study

Get alerted when new AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY ENTERITIS trials appear

Sign up with your email to follow new studies for AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY ENTERITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New hope for controlling rare autoimmune gut disease

Disease control Recruiting now

This study is testing a drug called emapalumab in people with APECED, a rare autoimmune disease that attacks the small intestine. The goal is to see if the drug can reduce gut inflammation and improve symptoms like diarrhea and pain. Participants will receive the drug through an …

Matched conditions: AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY ENTERITIS

Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control

Last updated Apr 03, 2026 14:43 UTC

AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY ENTERITIS

Get alerted when new AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY ENTERITIS trials appear

New hope for controlling rare autoimmune gut disease